+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 100Years
All Genders
ID07665437

Long-term Safety and Efficacy Study of Two Remibrutinib Doses in Adults With Moderate to Severe Hidradenitis Suppurativa A Multicenter Phase 3 Double-blind Extension Trial

Led by Novartis Pharmaceuticals · Updated on 2026-10-13

710

Participants Needed

44

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the long-term safety, tolerability, and effectiveness of remibrutinib in adults with moderate to severe hidradenitis suppurativa who have finished previous Phase 3 studies. This global Phase 3 extension trial continues to evaluate remibrutinibs impact over several years, fulfilling commitments to provide continued access to the treatment. Participants will continue their assigned blinded dose of remibrutinib from the prior studies until final analysis or dose adjustment. Afterward, treatment shifts to an open-label phase, lasting until commercial availability, reimbursement, alternative access, or four years of extension treatment are completed. Those ending treatment early or not transitioning to commercial remibrutinib enter a four-week safety follow-up without treatment. Throughout the study, participants undergo regular monitoring for adverse events and treatment responses using scales such as the International Hidradenitis Suppurativa Severity Score System and clinical response measures up to week 276. The study emphasizes safety and long-term effects, with participation lasting up to several years including follow-up, ensuring comprehensive data collection on remibrutinibs use in this condition.

CONDITIONS

Brief Title

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here